An Exploratory Phase II Study of PHA-739358 in Patients With Multiple Myeloma Harbouring the t(4;14) Translocation With or Without FGFR3 Expression
Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care
Response Rate according to International Myeloma Working Group uniform response criteria for multiple myeloma.
At end of each cycle
United States: Food and Drug Administration
|Mayo Clinic||Scottsdale, Arizona|
|The Robert H Lurie Comprehensive Cancer Center, Northwestern University||Chicago, Illinois 60611|